Skip to main content

Table 1 Pigs vaccinated with E2 subunit vaccine did not develop viremia after CSFV challenge

From: Pigs immunized with a novel E2 subunit vaccine are protected from subgenotype heterologous classical swine fever virus challenge

Serum

3 DPC

6 DPC

9 DPC

12 DPC

15 DPC

Treatment

Pig #

Ct value

TCID50

Ct value

TCID50

Ct value

TCID50

Ct value

TCID50

Ct value

TCID50

(−/−)

51

(−)

(−)

ND

ND

ND

ND

ND

ND

ND

ND

(−/−)

52

37

98

ND

ND

ND

ND

(−)

(−)

(−)

(−)

(−/−)

53

(−)

(−)

(−)

(−)

ND

ND

(−)

(−)

36

112

(−/−)

54

(−)

(−)

(−)

(−)

(−)

(−)

(−)

(−)

(−)

(−)

(−/−)

55

(−)

(−)

(−)

(−)

(−)

(−)

(−)

(−)

(−)

(−)

(−/+)

56

(−)

(−)

29

4330

30

2774

28

17,617

35

163

(−/+)

57

36

78

25

47,547

20

1,460,325

19

4,993,009

21

1,036,940

(−/+)

58

(−)

(−)

28

7090

23

222,328

20

2,587,042

21

1,095,457

(−/+)

59

(−)

(−)

26

28,553

22

480,384

pig died

   

(−/+)

60

(−)

(−)

29

5169

22

507,102

21

1,019,529

21

1,003,013

One-dose

61

37

42

28

7192

35

160

38

29

38

58

One-dose

62

(−)

(−)

34

170

(−)

(−)

39

21

(−)

(−)

One-dose

63

34

179

35

160

36

68

(−)

(−)

(−)

(−)

One-dose

64

36

56

33

330

34

169

36

131

(−)

(−)

One-dose

65

(−)

(−)

35

100

(−)

(−)

(−)

(−)

(−)

(−)

Two-dose

66

(−)

(−)

36

56

35

106

(−)

(−)

(−)

(−)

Two-dose

67

(−)

(−)

34

279

(−)

(−)

(−)

(−)

(−)

(−)

Two-dose

68

(−)

(−)

36

85

(−)

(−)

(−)

(−)

(−)

(−)

Two-dose

69

(−)

(−)

(−)

(−)

(−)

(−)

(−)

(−)

(−)

(−)

Two-dose

70

(−)

(−)

35

97

(−)

(−)

(−)

(−)

(−)

(−)

  1. ND not done; (−): Undetectable; Pigs were challenged with CSFV 35 days post first vaccination. CSFV RNA in the blood was measured by real-time RT-PCR as described in Methods section
  2. (−/−): Control pigs without CSFV challenge; (−/+): Control pigs challenged with CSFV
  3. One-dose: Pigs vaccinated with one dose KNB-E2 and then challenged with CSFV
  4. Two-dose: Pigs vaccinated with KNB-E2 twice and then challenged with CSFV